Sikkim Journal

Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is a digital technology and biotechnology organization that develops innovative novel compounds that help in treating mental health and addiction. It uses high-class technology and drug development infrastructure for developing these second and third-generation compounds. 

The medical and scientific advisory board is researching and developing novel compounds, therapies, drug delivery systems, and psychedelic derived therapeutics.

Mydecine Innovations Group has signed a Letter of Intent or LOI with Maya. The two companies will jointly develop a novel digital therapeutics platform. It will help Mydecine for enhancing the effectiveness of the treatment by pairing the DTx to the digital health platform Mindleap Health. It will be along with the company’s medicine-based treatments for achieving a triple approach.

The company also announced that they have finished a model of the psychedelic serotonin receptor 5-HT2A for use in the AI-driven drug discovery program. With this new model, they will determine the novel compounds that can increase binding affinity. This will lead to creating second and third-generation psychedelic molecules for medicinal purposes.

Innovation and advancement have been made in treating cancer, diabetes, and other diseases. But similar steps have not been taken in treating mental health disorders like PTSD and depression. With the compounds developed by Mydecine, there is a growing chance of treating mental health disorders properly. 

The company has signed a five-year research agreement with Johns Hopkins University School of Medicine. With this, conditions like anxiety and depression can be combated. 

They also announced the launch of a phase 2/3 smoking cessation clinical trial with Johns Hopkins University. With such associations, Mydecine is looking forward to changing mental health and addiction treatment among individuals.

Learn more at: https://smallcapexclusive.com/mydecine-otcmycof-neomyco-is-undervalued-mydecine-has-an-incredible-pps-target-take-a-look

About Mydecine Innovations Group:

Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is a digital technology and biotechnology organization that develops innovative novel compounds that help treat different mental health conditions and addiction.

For more information, visit https://www.mydecine.com/investors/company-information

Disclaimer: This article is purely for informational purposes and is not a recommendation in any way to buy or sell stocks.

Media Contact
Company Name: Mydecine Innovations Group
Contact Person: Investor Relations
Email: Send Email
Country: Canada
Website: www.mydecine.com